Chelsea Therapeutics just received FDA approval for its drug Northera. In no time flat, the company was snatched up by a bigger pharmaceutical company.
Over the past five years, emerging markets have done a whole lot of nothing. But the smart money is moving into them now...
With strong first quarter revenue and income growth, First Solar is expecting a big 2014.
Solar power's growing presence in the world is helping companies like Canadian Solar beat their own guidance.
Energy and Capital editor Keith Kohl reports on a small Texas town on the verge of banning hydraulic fracturing in the Barnett Shale.
It's billed as safe and clean, but that may not be enough to give a boost to hydro. This, despite a new DOE report which suggests we could easily double our hydro contributions.
SolarCity has a new collaboration. This time with HVAC company Carrier.
Your children and grandchildren will likely end up working for an oil and gas company.
Energy and Capital editor Keith Kohl takes a hard look at why South Texas is just one reason for investors to get their own piece of U.S. shale profits.
Energy and Capital editor Keith Kohl uncovers BP's new weapon to fight dwindling reserves.
Boston-based Lucidity Lights has revealed the new 60W replacement lightbulb it's been working on for the last two years.
Energy and Capital editor Keith Kohl comments on the role that China will play in the upcoming debate over U.S. LNG exports.
ENERGY AND CAPITAL
3 EAST READ ST
BALTIMORE, MD 21202
TEL: (877) 303-4529
FAX: (410) 814-5959
© ENERGY AND CAPITAL. ALL RIGHTS RESERVED.
